Factors affecting susceptibility of Staphylococcus aureus to antibacterial agents  by Kawada-Matsuo, Miki & Komatsuzawa, Hitoshi
Journal of Oral Biosciences 54 (2012) 86–91Contents lists available at SciVerse ScienceDirectJournal of Oral Biosciences1349-00
http://d
n Corr
Graduat
City, Ka
E-mjournal homepage: www.elsevier.com/locate/jobReviewFactors affecting susceptibility of Staphylococcus aureus
to antibacterial agentsMiki Kawada-Matsuo, Hitoshi Komatsuzawa n
Department of Oral Microbiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japana r t i c l e i n f o
Article history:
Received 21 April 2011
Received in revised form
28 July 2011
Accepted 30 July 2011
Available online 29 May 2012
Keywords:
MRSA
Cell wall biosynthesis
Vancomycin
Antimicrobial peptide79/$ - see front matter & 2012 Japanese Asso
x.doi.org/10.1016/j.job.2012.04.001
espondence to: Department of Oral Microbi
e School of Medical and Dental Sciences, Sak
goshima 890-8544, Japan. Tel.: þ81 99 275 6
ail address: hkomatsu@dent.kagoshima-u.ac.ja b s t r a c t
Staphylococcus aureus is a major human pathogen that causes suppurative diseases, toxic shock syndrome,
pneumonia, food poisoning, and staphylococcal scalded skin syndrome (SSSS). S. aureus can also cause
osteomyelitis and radicular cysts that impact dental health. b-lactam antibiotics are frequently used for the
treatment of S. aureus infections, but the emergence of methicillin-resistant S. aureus (MRSA) has caused
serious problems for the antibiotic treatment of S. aureus infections. PBP20 has a low afﬁnity for methicillin
antibiotics and is one of the factors responsible for resistance to these antibiotics. However, clinical MRSA
isolates show various levels of resistance to methicillin that are not determined by the amount of PBP20 ,
indicating that other factors are also involved. Furthermore, while vancomycin is very effective against
MRSA, vancomycin-resistant and vancomycin-intermediate S. aureus have recently been reported. Many
studies have been undertaken to better understand methicillin and vancomycin resistance mechanisms
through identiﬁcation of the factors affecting susceptibility to b-lactams. We recently demonstrated that
MRSA showed resistance to antimicrobial peptides produced by humans that are a component of the innate
immune system, in addition to various antibiotics.
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Staphylococcus aureus is a major pathogenic bacterium that causes
various diseases in humans. S. aureus infection sometimes leads to
infectious skin diseases (impetigo, furuncle, carbuncle, and staphylo-
coccal scalded skin syndrome: SSSS), respiratory infectious disease,
enteritis, osteomyelitis, sepsis, and endocarditis [1,2]. In the ﬁeld of
dentistry, S. aureus is known to cause osteomyelitis, pericoronitis, and
radicular cysts. Because S. aureus is an opportunistic pathogen, it is
usually resident in, the nasal cavity, the oral cavity, the intestines, and
on skin. About 30–40% of people possess this bacterium.ciation for Oral Biology. Published
ology, Kagoshima University
uragaoka 8-35-1, Kagoshima
150; fax: þ81 99 275 6158.
p (H. Komatsuzawa).S. aureus has become a clinically signiﬁcant problem as a major
pathogen for nosocomial infection because most S. aureus strains
have acquired resistance to various antimicrobial agents [3]. The
emergence of penicillin-resistant strains that produce penicillinase
was reported in 1947 and methicillin-resistant S. aureus (MRSA)
emerged in the United Kingdom in 1967. Since the emergence of
MRSA, it has spread rapidly around the world. In Japan, reports
of MRSA infection have increased since 1980. Glycopeptides,
vancomycin, and teicoplanin are effective treatments for MRSA
infection, but vancomycin-intermediate S. aureus (VISA) and
vancomycin-resistant S. aureus (VRSA) have been reported [4,5].
Since the emergence of MRSA, many researchers have studied
the antibiotic resistance of MRSA, especially b-lactam and vanco-
mycin resistance. Recently, S. aureus genome analysis has pro-
vided useful information for the study of virulence and antibiotic
resistance and for epidemiological analyses.by Elsevier B.V. All rights reserved.
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PBP20, which has low afﬁnity for these antibiotics [6]. In addition,
vancomycin resistance in S. aureus is mediated by VanA (vanA) [5].
However, the mechanisms underlying the variation in b-lactam
resistance level or low susceptibility to vancomycin in clinically
isolated MRSA are not clear. Many investigators, including our
group, are therefore studying the factors that affect susceptibility
to b-lactams and vancomycin. While studying b-lactam resistance
in MRSA, we have begun to evaluate factors related to antimicro-
bial peptide resistance. Antimicrobial peptides comprise one of
the innate immune system components in humans.
In this article, we review the current research on b-lactam and
vancomycin resistance and present our ﬁndings. We also introduce
the mechanism of S. aureus resistance against antimicrobial peptides.
2. b-Lactam resistance
There have been many studies of b-lactam resistance in MRSA.
The key molecule conferring resistance against b-lactams is a
penicillin-binding-protein, PBP20 (2A) [6]. Methicillin-susceptible
S. aureus (MSSA) possesses 4 PBPs, known as PBP1–4. In MSSA
strains, all PBPs are inactivated in the presence of b-lactams,
leading to cell death that is caused by inhibition of the transpep-
tidase reaction, one of the ﬁnal steps in cell wall biosynthesis
(Fig. 1). In contrast, MRSA survives in the presence of b-lactams
because an extra PBP20 that is speciﬁc to MRSA has a low afﬁnity
for this group of antibiotics. It retains its activity in the presence
of b-lactams, allowing cell wall biosynthesis to continue (Fig. 1).
The MecR1–MecI system was identiﬁed as a regulatory factor for
PBP20 expression [7], but the effects of this regulatory system on
the methicillin resistance level of clinical isolates have not been
fully determined. In addition, a genetic mobile element contain-
ing the mecA gene, called SCCmec, is believed to be transferred
between staphylococci [8]. SCCmec is classiﬁed into 7 groups, and
SCCmec typing is useful for epidemiological studies of MRSA [9].Fig. 1. b-Lactam-resistance mechanism in S. aureus. In MSSA, all PBPs are inactivated
presence of b-lactams because a PBP that is speciﬁc for MRSA, PBP20 , has a low afﬁnityClinically isolated MRSA strains have a variety of methicillin
resistance levels, with high, moderate, and low resistance to
b-lactams. This variation in resistance is due to ‘‘heterogeneous
resistance’’ [10,11]. This means that only a small proportion of colony
forming units are able to express resistance in response to different
concentrations of b-lactam antibiotics. Bacteria with homogeneous
resistance show a uniform reaction against different concentrations
of these antibiotics. Most clinically isolated strains show the hetero-
geneous-resistant pattern, leading to diversity of resistance.
To identify the factors related to the variety of resistance
levels, a transposon–mutagenesis method has been used to
isolate mutants with decreased resistance levels. The factor
involved in this decrease is then identiﬁed by analyzing transpo-
son insertion sites [11]. The ﬁrst factor identiﬁed using this
method was femA (factor essential for expression of methicillin
resistance), which is involved in the formation of the glycine
pentamer of peptidoglycan cross-linked structures [12]. Several
other factors have also been identiﬁed using the same method.
We attempted to identify new factors using a similar approach.
Although most factors affecting methicillin resistance were iden-
tiﬁed by Tn551-mediated insertional inactivation followed by
screening for increased susceptibility to methicillin, we used a
modiﬁed screening method to isolate the mutants. In an earlier
study, we found that non-inhibitory concentrations of Triton
X-100 reduced the oxacillin (methicillin)-resistance level of
MRSA [13]. The degree of Triton X-100-induced sensitization
varies among strains, suggesting that the factors responsible for
the expression of methicillin resistance differ between strains
and depend on their speciﬁc genetic background. Therefore, we
attempted to isolate a Tn551 insertional mutant of the MRSA COL
strain that became more susceptible to oxacillin in the
presence of 0.02% Triton X-100. Using this approach, we identiﬁed
3 factors [14–16] that we designated fmtA, B, and C (fmt: the
factor responsible for methicillin resistance in the presence of
Triton X-100). The characteristics of each of these factors include:in the presence of b-lactams, leading to cell death (top). MRSA survives in the
for b-lactams and retains its activity in the presence of these antibiotics (bottom).
Table 1
Factors affecting the susceptibility to methicillin and/or vancomycin.
1M: methicillin, V: vancomycin.
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FmtA: FmtA has 2 of 3 conserved motifs that are typically
found in penicillin-binding proteins (PBPs) and b-lactamases.
Immunoblotting analysis revealed that FmtA is localized in
the membrane fraction. Because the mutant had reduced
cross-linking and partially reduced amidation of glutamate
residues in peptidoglycan, it was suggested that FmtA affects
the cell wall structure [15]. A subsequent report indicated
that FmtA is able to bind to penicillin, thereby revealing that
FmtA is a new penicillin-binding protein [17].(2) FmtB: The fmtB gene codes for a protein with a deduced
molecular mass of 263 kDa that contains 17 tandem repeats of
75 amino acids and a C-terminal LPXTG cell wall-sorting motif
[16]. Mutation of fmtB reduces oxacillin resistance. Immunoblot
analysis indicates that FmtB is localized in the cell wall fraction.(3) FmtC: FmtC has been referred to as MprF in subsequent
studies [18]. MprF is an enzyme that transfers lysine to
phosphatidylglycerol, which is a component of the cell mem-
brane. In an mprF mutant, an unusual modiﬁcation leads to
a reduced negative charge of the membrane surface and
increased binding of antimicrobial peptides to the bacteria.
However, the relationship between FmtC (MprF) and
b-lactam resistance is still unknown.There are many recognized factors that affect methicillin resis-
tance level (Table 1) [19,20]. Most of these factors are associated
with cell wall biosynthesis. In addition, several transcriptional
regulators have been identiﬁed, indicating that some regulators
are responsible for cell wall biosynthesis [20]. Although many
factors that affect methicillin resistance have been determined, thereason for the variety of resistance levels in MRSA is still unknown
because methicillin resistance level is mediated by complicated
mechanisms or the mechanisms differ between strains.3. Vancomycin resistance and intermediate resistance
Glycopeptides, such as vancomycin and teicoplanin, are effec-
tive against MRSA infections, but VISA or glycopeptide-intermedi-
ate S. aureus (GISA) strains have now been isolated in several
countries [4,21]. Intermediate susceptibility is mediated by cell
wall thickening and reduced cross-linking, which facilitates the
trapping vancomycin within the layers of cell wall peptidoglycan.
This prevents the vancomycin from reaching the peptidoglycan
precursor that is attached to the cell membrane [22,23] (Fig. 2).
Although some factors affecting vancomycin susceptibility have
been reported [24–27], the exact mechanism of cell wall thicken-
ing and intermediate susceptibility and the entire complement of
factors associated with them remain unknown. Recently, strains
highly resistant to vancomycin that contain the enterococcal vanA
gene have also emerged [5] The mechanism of the resistance of
these strains is clearly distinct from that found in VISA strains.
VanA is associated with an altered peptidoglycan precursor
structure, changing a D-alanine-D-alanine structure to D-alanine-
D-lactate. This alteration causes inhibition of vancomycin binding
to the peptidoglycan precursor (Fig. 3).
We previously isolated a spontaneous VISA mutant from a
MRSA COL strain by exposing it to vancomycin [23]. Characteriza-
tion of the mutant revealed that it contained a longer glycan chain
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Fig. 2. Vancomycin intermediate-resistance mechanism in S. aureus. Cell wall thickness and reduced cross-linking in cell wall peptidoglycans increase the vancomycin
binding sites in the cell wall, preventing the binding of vancomycin to the peptidoglycan precursor. M: N-acetylmuramic acid, G: N-acetylglucosamine, D-Lac: D-lactate,
D-Ala: D-alanine, L-Lys: L-lysine, D-Gln: D-glutamine.
Fig. 3. Vancomycin resistance mechanism in S. aureus. Vancomycin resistance in S. aureus is mediated by VanA (vanA), which is involved in alteration of the peptidoglycan
structure (converting D-Ala-D-Ala to D-Ala-D-Lac).
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susceptibility than the MRSA COL bacteria. Moenomycin is a cell
wall synthesis inhibitor that acts on transglycosylases. Transgly-
cosylases are thought to mediate the formation of the peptidogly-
can glycan chains and the incorporation of the peptidoglycan
precursor into cell-wall peptidoglycan [28]. Vancomycin also
inhibits cell wall synthesis, although its target is different from
that of moenomycin. Vancomycin binds to terminal D-Ala-D-Alaresidues of the peptidoglycan precursor, thus inhibiting peptido-
glycan chain elongation [29]. We isolated moenomycin-resistant
mutants from a MRSA COL strain by exposing it to moenomycin
[30]. These mutants also had a longer glycan chain length than
found in MRSA COL and a vancomycin-intermediate-resistance
phenotype. This strongly suggests that moenomycin resistance is
associated with intermediate resistance to vancomycin. Therefore,
identiﬁcation of the factors that affect moenomycin susceptibility
Fig. 4. Susceptibility of 494 S. aureus strains to in vitro exposure to hBD3 and LL-37. MRSA strains were divided into 3 subgroups (L-MRSA, M-MRSA, and H-MRSA). The percentage
survival of S. aureus strains (MSSA and the 3 subgroups of MRSA) after exposure to hBD3 (2 mg/L) or LL-37 (1 mg/L) is shown. *, **, and *** indicate signiﬁcant differences between
the groups connected by brackets (po0.05, po0.01, and po0.001, respectively). Signiﬁcant differences were determined by Student’s t-test (Ref. [34]).MSSA: methicillin-
susceptible S. aureus, L-MRSA: low-methicillin-resistant S. aureus, M-MRSA: moderate-methicillin-resistant S. aureus, H-MRSA: high-methicillin-resistant S. aureus.
Fig. 5. Factors affecting cell surface charge. ApsSR positively regulates the expression of dlt and fmtC (mprF), which are associated with cell surface charge. AgrA negatively
regulates the expression of apsRS.
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ibility to vancomycin. We isolated Tn551-insertional mutants,
which had decreased susceptibility to both moenomycin and
vancomycin. We identiﬁed the causes (fmtC and lysC) of their
vancomycin and moenomycin susceptibility [31].
The factors affecting intermediate susceptibility to vancomy-
cin are shown in Table 1. Factors affecting methicillin resistance,
cell wall biosynthesis, and transcriptional regulators are all
involved in intermediate susceptibility to vancomycin. Further
study is needed to clarify the precise mechanism of vancomycin
intermediate susceptibility.4. Resistance to antimicrobial peptides
During our research on methicillin and vancomycin resistance,
we found that the surface charge of the bacterial cell was associated
with their susceptibility to the charged antibacterial agents vanco-
mycin, gentamicin, and cationic antimicrobial peptides [31]. Catio-
nic antimicrobial peptides, such as defensins and LL37, are produced
by humans and are responsible for innate immunity. We investi-
gated the relationship between susceptibility to antimicrobial pep-
tides and cell surface charge in 2 sets of experiments.1) Evaluation of susceptibility to antimicrobial peptides in
clinical isolates.Human epithelia produce cationic antimicrobial peptides, includ-
ing 4 distinct b-defensins (hBD1–4) and 1 cathelicidin family
peptide (LL-37) [32,33]. We evaluated the susceptibility of 494
strains of S. aureus clinical isolates to 2 cationic antimicrobial
peptides, hBD3 and LL-37 (Fig. 4) [34]. MRSA strains were
signiﬁcantly more resistant to hBD3 and LL-37 than were MSSA
strains. In addition, those strains that were highly resistant to
methicillin were also signiﬁcantly more resistant to LL-37, but
not to hBD3, than other strains. This suggests that MRSA is
resistant not only to various antibiotics, but also to antimicrobial
peptides, part of the innate immune system of humans.2) Regulation of the cell surface charge in S. aureus.
Aps is a 2-component system (TCS) that regulates the FmtC
(MprF) that is responsible for incorporating lysine into phospha-
tidylglycerol, a major component of bacterial membrane. It also
regulates DltC, which incorporates alanine into teichoic acids.
Recently, Aps was reported to affect the charge of the cell surface
(Fig. 5) [35,36]. TCSs are prokaryote-speciﬁc signal transduction
systems that consist of a gene that encodes a sensory histidine
kinase and a gene that encodes a cognate response regulator
(RR). Bacteria can adapt to the external environment and
regulate gene expression using this system. We demonstrated
that Aps was expressed strongly in the exponential phase,
whereas its expression was signiﬁcantly suppressed by Agr in
the stationary phase. This resulted in higher expression of DltC
and MprF in the exponential phase and lower expression in the
M. Kawada-Matsuo, H. Komatsuzawa / Journal of Oral Biosciences 54 (2012) 86–91 91stationary phase [37]. Because the cell surface charge was
affected differently in each phase, susceptibility to AMP and
cationic antibiotics changed during growth. Furthermore, we
found that bacteria could only sense AMP during the exponential
phase. These results suggest that the cell surface charge is tightly
regulated during growth in S. aureus.
5. Conclusions
MRSA in hospitals is still a serious problem, and recently,
community-acquired MRSA has emerged as a cause of infectious
disease. From studies on its susceptibility to antibacterial agents,
we identiﬁed factors that are responsible for antibiotic resistance
and are related to other features, such as the physiology of cell wall
biosynthesis; the regulatory machinery of genes, including viru-
lence factors; and bacterial interaction with host immune factors.
Study of the mechanisms underlying the resistance to antibacterial
agents is helpful for developing effective chemotherapy, discovery
of new antibacterial agents, and analysis of MRSA evolution.Conﬂict of interest
No potential conﬂicts of interest are disclosed.Acknowledgments
We thank Dr. Hidekazu Suginaka and Prof. Motoyuki Sugai for
their encouragement and helpful advice. We are also grateful to
the laboratory members of Hiroshima University Graduate School
of Biomedical Sciences and Kagoshima University of Medical and
Dental Sciences.
References
[1] Foster TJ. The Staphylococcus aureus ‘‘superbug’’. J Clin Invest 2004;114:
1693–6.
[2] Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520–32.
[3] Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and
resurgence of methicillin-resistant Staphylococcus aureus as a public-health
threat. Lancet 2006;368:874–85.
[4] Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced
vancomycin susceptibility in Staphylococcus aureus, including vancomycin-
intermediate and heterogeneous vancomycin-intermediate strains: resis-
tance mechanisms, laboratory detection, and clinical implications. Clin
Microbiol Rev 2010;23:99–139.
[5] Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP,
Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK. Infection with
vancomycin-resistant Staphylococcus aureus containing the vanA resistance
gene. N Engl J Med 2003;348:1342–7.
[6] Ubukata K, Nonoguchi R, Matsuhashi M, KonnoM. Expression and inducibility in
Staphylococcus aureus of themecA gene, which encodes a methicillin-resistant S.
aureus-speciﬁc penicillin-binding protein. J Bacteriol 1989;171:2882–5.
[7] Garcia-Castellanos R, Mallorqui-Fernandez G, Marrero A, Potempa J, Coll M,
Gomis-Ruth FX. On the transcriptional regulation of methicillin resistance: MecI
repressor in complex with its operator. J Biol Chem 2004;279:17888–96.
[8] Hanssen AM, Ericson Sollid JU. SCCmec in staphylococci: genes on the move.
FEMS Immunol Med Microbiol 2006;46:8–20.
[9] Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus.
Infect Genet Evol 2008;8:747–63.
[10] Hartman BJ, Tomasz A. Expression of methicillin resistance in heterogeneous
strains of Staphylococcus aureus. Antimicrob Agents Chemother 1986;29:85–92.
[11] de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of
methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother
1994;33:7–24.
[12] Berger-Bachi B, Barberis-Maino L, Strassle A, Kayser FH. FemA, a host-
mediated factor essential for methicillin resistance in Staphylococcus aureus:
molecular cloning and characterization. Mol Gen Genet 1989;219:263–9.
[13] Komatsuzawa H, Suzuki J, Sugai M, Miyake Y, Suginaka H. The effect of Triton
X-100 on the in-vitro susceptibility of methicillin-resistant Staphylococcus
aureus to oxacillin. J Antimicrob Chemother 1994;34:885–97.[14] Komatsuzawa H, Ohta K, Fujiwara T, Choi GH, Labischinski H, Sugai M.
Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance
in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 2001;203:
49–54.
[15] Komatsuzawa H, Ohta K, Fujiwara T, Choi GH, Labischinski H, Sugai M. Cloning
and characterization of the fmt gene which affects the methicillin resistance
level and autolysis in the presence of triton X-100 in methicillin-resistant
Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:2355–61.
[16] Komatsuzawa H, Ohta K, Sugai M, Fujiwara T, Glanzmann P, Berger Bachi B,
Suginaka H. Tn551-mediated insertional inactivation of the fmtB gene
encoding a cell wall-associated protein abolishes methicillin resistance in
Staphylococcus aureus. J Antimicrob Chemother 2000;45:421–31.
[17] Fan X, Liu Y, Smith D, Konermann L, Siu KW, Golemi-Kotra D. Diversity of
penicillin-binding proteins. Resistance factor FmtA of Staphylococcus aureus.
J Biol Chem 2007;282:35143–52.
[18] Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H,
Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KP, van Strijp J.
Staphylococcus aureus resistance to human defensins and evasion of neutro-
phil killing via the novel virulence factor MprF is based on modiﬁcation of
membrane lipids with l-lysine. J Exp Med 2001;193:1067–76.
[19] McCallum N, Berger-Bachi B, Senn MM. Regulation of antibiotic resistance in
Staphylococcus aureus. Int J Med Microbiol 2010;300:118–29.
[20] Berger-Bachi B, Rohrer S. Factors inﬂuencing methicillin resistance in
staphylococci. Arch Microbiol 2002;178:165–71.
[21] Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B,
Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. Emergence of vanco-
mycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Sta-
phylococcus aureus working group. N Engl J Med 1999;340:493–501.
[22] Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of
a thickened cell wall and its glutamine nonamidated component to the
vancomycin resistance expressed by Staphylococcus aureusMu50. Antimicrob
Agents Chemother 2000;44:2276–85.
[23] Komatsuzawa H, Ohta K, Yamada S, Ehlert K, Labischinski H, Kajimura J,
Fujiwara T, Sugai M. Increased glycan chain length distribution and
decreased susceptibility to moenomycin in a vancomycin-resistant Staphy-
lococcus aureus mutant. Antimicrob Agents Chemother 2002;46:75–81.
[24] Bischoff M, Roos M, Putnik J, Wada A, Glanzmann P, Giachino P, Vaudaux P,
Berger-Bachi B. Involvement of multiple genetic loci in Staphylococcus aureus
teicoplanin resistance. FEMS Microbiol Lett 2001;194:77–82.
[25] Boyle-Vavra S, de Jonge BL, Ebert CC, Daum RS. Cloning of the Staphylococcus
aureusddh gene encoding NADþ-dependent D-lactate dehydrogenase and
insertional inactivation in a glycopeptide-resistant isolate. J Bacteriol
1997;179:6756–63.
[26] Moreira B, Boyle-Vavra S, deJonge BL, Daum RS. Increased production of
penicillin-binding protein 2, increased detection of other penicillin-binding
proteins, and decreased coagulase activity associated with glycopeptide resis-
tance in Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1788–93.
[27] Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. Teicoplanin-
resistant Staphylococcus aureus expresses a novel membrane protein and
increases expression of penicillin-binding protein 2 complex. Antimicrob
Agents Chemother 1993;37:2432–7.
[28] Huber G, Nesemann G. Moenomycin, an inhibitor of cell wall synthesis.
Biochem Biophys Res Commun 1968;30:7–13.
[29] Barna JC, Williams DH. The structure and mode of action of glycopeptide
antibiotics of the vancomycin group. Annu Rev Microbiol 1984;38:339–57.
[30] Nishi H, Komatsuzawa H, Yamada S, Fujiwara T, Ohara M, Ohta K, Sugiyama
M, Ishikawa T, Sugai M. Moenomycin-resistance is associated with vanco-
mycin-intermediate
susceptibility in Staphylococcus aureus. Microbiol Immunol 2003;47:927–35.
[31] Nishi H, Komatsuzawa H, Fujiwara T, McCallum N, Sugai M. Reduced content of
lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility
to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides,
in Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:4800–7.
[32] Ganz T, Lehrer RI. Defensins. Pharmacol Ther 1995;66:191–205.
[33] Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a
novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995;63:
1291–7.
[34] Ouhara K, Komatsuzawa H, Kawai T, Nishi H, Fujiwara T, Fujiue Y, Kuwabara
M, Sayama K, Hashimoto K, Sugai M. Increased resistance to cationic
antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus
aureus. J Antimicrob Chemother 2008;61:1266–9.
[35] Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M. The antimicrobial
peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol 2007;66:
1136–47.
[36] Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. Inactivation of the
dlt operon in Staphylococcus aureus confers sensitivity to defensins, prote-
grins, and other antimicrobial peptides. J Biol Chem 1999;274:8405–10.
[37] Matsuo M, Oogai Y, Kato F, Sugai M, Komatsuzawa H. Growth-phase
dependence of susceptibility to antimicrobial peptides in Staphylococcus
aureus. Microbiology 2011;157:1786–97.
